Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Private sector driving pharma R&D, finds study
The PSA test, as well as how it is used to guide patient care (e.g., at what age men should begin regular testing, intervals at which the test
The PSA test, as well as how it is used to guide patient care (e.g., at what age men should begin regular testing, intervals at which the test
Aspergillus fumigatus Fresenius, the fungus used in the study was accidentally discovered 20 years ago, by Harvard researcher Donald Ingber. It was experimentally named as TNP-470 and was
Under the terms of the agreement, Altea Therapeutics has granted Hospira exclusive worldwide rights to develop and commercialize the product. Altea Therapeutics will fund certain Phase I clinical
Participating in the internal round were Pearl’s existing investors Clarus Ventures, New Leaf Ventures, 5AM Ventures and Nektar Therapeutics. In total, Pearl has raised $36.4 million of venture
The ‘Miniature Microscope’, a 3.4mm 3D camera is used in tran-nasal skull-base and other minimally invasive neurosurgical procedures, providing a local stereoscopic view of the anatomy. The company
Cubist will promote and support Merrem IV using its existing US acute care sales and medical affairs organizations. AstraZeneca will continue to provide marketing and commercial support for
The company expects to enroll approximately 240 patients at a single center in the US. This randomized, placebo-controlled, double-blind, parallel group study is designed to evaluate the efficacy
Lloyd Malchow, SenoRx president and CEO, said: “The novel proprietary design of our newest Contura multi-lumen radiation balloon catheter allows the clinician greater flexibility in appropriately fitting the
Joe Oliverio, president of Positron, said: “We are grateful to the University of Texas Health Science Center at Houston and Dr Gould for selecting Positron as the exclusive
The financing will be used to further develop a migraine compound, COL-144, and to advance a preclinical pipeline of novel chemical entities targeting neurological and psychiatric disorders. The